cfDNA analysis in ovarian cancer can be used for early detection, disease monitoring, determining response to treatment and detection of minimal/molecular residual disease (MRD) and for identification of specific genetic alterations, such as BRCA1/2 mutations, that may be present in ovarian cancer (184). The gene discussed is BRCA1; the disease is ovarian cancer.